Cartesian Therapeutics downgraded by Oppenheimer
$RNAC
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer downgraded Cartesian Therapeutics from Outperform to Perform
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/19/2024 | $42.00 | Buy | BTIG Research |
| 8/6/2024 | Buy | TD Cowen | |
| 7/2/2024 | Outperform → Perform | Oppenheimer | |
| 6/4/2024 | $50.00 | Outperform | Oppenheimer |
| 5/24/2024 | $40.00 | Buy | Mizuho |
| 4/23/2024 | $2.00 → $54.00 | Buy | H.C. Wainwright |
| 4/23/2024 | $39.00 | Outperform | Leerink Partners |
FREDERICK, Md., June 03, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On June 2, 2025, the Company issued to these employees options to purchase an aggregate of 26,350 shares of the Company's common stock with an exercise price of $9.98, the closing trading price of the Company's common stock on the Nasdaq Global Market on the date of grant. The options were granted pursuant to the Company's Amended and Restated 2018 Employment Inducement Incentive Award Plan and were approved by the Company
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that the first participant has been enrolled in its Phase 3 AURORA trial of Descartes-08 in patients with myasthenia gravis (MG). Descartes-08, Cartesian's lead cell therapy candidate, is an autologous engineered chimeric antigen receptor T-cell therapy (CAR-T) product candidate targeting B-cell maturation antigen (BCMA). Descartes-08 is designed to be administered without preconditioning chemotherapy in an outpatient setting and does not use integrating vectors.
FREDERICK, Md., May 13, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in a fireside chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 20, 2025, at 9:00 a.m. ET. A live webcast of the presentation and fireside chat is expected to be accessible in the Events section of the Company's website at www.cartesiantherapeutics.com, where an archived replay of the events will also be available for a limited time. About Cartesian Therapeutics Cartesian Therapeutics is a
8-K - Cartesian Therapeutics, Inc. (0001453687) (Filer)
S-8 - Cartesian Therapeutics, Inc. (0001453687) (Filer)
10-Q - Cartesian Therapeutics, Inc. (0001453687) (Filer)
Phase 3 AURORA trial on track to commence in 1H2025; Primary endpoint to assess proportion of Descartes-08-treated participants with myasthenia gravis demonstrating an MG-ADL improvement of ≥3 points at Month 4 relative to placebo Deepening responses observed over time in Phase 2b trial, with Descartes-08-treated participants observed to have a 5.5-point reduction in MG-ADL at Month 4 Durable responses observed through Month 12 in Phase 2b trial Safety profile consistent with previously reported data and continues to support outpatient administration Company to host conference call and webcast with key opinion leader today at 7:30 a.m. ET FREDERICK, Md., Dec. 03, 2024 (GLOB
FREDERICK, Md., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced that updated efficacy and safety data from the Phase 2b trial of Descartes-08 in patients with generalized myasthenia gravis will be presented at the 2nd Annual Cell Therapy for Autoimmune Disease Summit, being held December 2-4, 2024 in Philadelphia. Details of the presentation are as follows: Title: Perspectives on Bringing Cell Therapies to the Autoimmune Space: From Concept to ClinicSession Name: Diving into Challenges & Successes in the Autoimmune Space to Direct Futu
Trial met primary endpoint with statistical significance, with 71% of myasthenia gravis patients treated with Descartes-08 observed to have a clinically meaningful improvement in MGC score at Month 3 compared to 25% for placebo Deep and durable responses up to at least six months observed in patients treated with Descartes-08 Safety profile continues to support outpatient administration Company expects to hold End-of-Phase 2 meeting with the FDA by year-end Company to host conference call today at 8:00 a.m. ET GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) ("Cartesian" or the "Company"), a clinical-stage biotechnology company pioneerin
Company expects to commence Phase 3 trial of Descartes-08 in patients with myasthenia gravis in 1H2025 following recent meeting with U.S. Food and Drug Administration Presentation of updated efficacy and safety data from Phase 2b trial and Phase 3 trial design of Descartes-08 in patients with myasthenia gravis expected by year-end Dosing underway in Phase 2 trial of Descartes-08 in patients with systemic lupus erythematosus Dosing underway in first-in-human Phase 1 trial of Descartes-15 Approximately $220.9M of cash, cash equivalents, and restricted cash as of September 30, 2024 expected to support planned operations, including completion of planned Phase
Presented positive topline results from Phase 2b trial of Descartes-08 in patients with myasthenia gravis; End-of-Phase 2 meeting with FDA expected by year-end Dosed first SLE patient in Phase 2 trial of Descartes-08 IND filing for pediatric basket study of Descartes-08 with focus in neurology and rheumatology expected by year-end PIPE financing strengthened balance sheet, with net proceeds expected to support development of Descartes-08 in MG through planned Phase 3 trial GAITHERSBURG, Md., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today rep
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ:RNAC) (the "Company"), a clinical-stage biotechnology company pioneering mRNA cell therapy for autoimmune diseases, today announced the appointment of Kemal Malik, MBBS to its Board of Directors. Dr. Malik brings to Cartesian over 30 years of global development, regulatory, and commercial expertise at leading pharmaceutical organizations. "We are thrilled to welcome Dr. Malik, a proven leader and industry veteran, to our Board of Directors," said Carsten Brunn, Ph.D., President and Chief Executive Officer of Cartesian. "His deep experience in successfully advancing innovative therapies through all st
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
BTIG Research initiated coverage of Cartesian Therapeutics with a rating of Buy and set a new price target of $42.00
TD Cowen initiated coverage of Cartesian Therapeutics with a rating of Buy
Oppenheimer downgraded Cartesian Therapeutics from Outperform to Perform
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
4 - Cartesian Therapeutics, Inc. (0001453687) (Issuer)
SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)
SC 13D/A - Cartesian Therapeutics, Inc. (0001453687) (Subject)